chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).
Company profile
Ticker
CDXC
Exchange
Website
CEO
Robert Fried
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CODY RESOURCES, INC.
SEC CIK
Corporate docs
Subsidiaries
ChromaDex, Inc. • ChromaDex International, Inc. • ChromaDex Analytics, Inc. • ChromaDex Europa B.V. • ChromaDex UK Limited • Asia Pacific Scientific, Inc. • ChromaDex Asia Limited • ChromaDex Asia Pacific Ventures Limited • ChromaDex Trading (Shanghai) Co., Ltd. ...
IRS number
262940963
CDXC stock data
Latest filings (excl ownership)
8-K
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Entry into a Material Definitive Agreement
13 Dec 23
8-K
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
424B5
Prospectus supplement for primary offering
6 Jul 23
EFFECT
Notice of effectiveness
6 Jul 23
CORRESP
Correspondence with SEC
30 Jun 23
Transcripts
CDXC
Earnings call transcript
2023 Q4
6 Mar 24
CDXC
Earnings call transcript
2023 Q3
8 Nov 23
CDXC
Earnings call transcript
2023 Q2
9 Aug 23
CDXC
Earnings call transcript
2023 Q1
10 May 23
CDXC
Earnings call transcript
2022 Q4
8 Mar 23
CDXC
Earnings call transcript
2022 Q3
2 Nov 22
CDXC
Earnings call transcript
2022 Q2
11 Aug 22
CDXC
Earnings call transcript
2022 Q1
13 May 22
CDXC
Earnings call transcript
2021 Q4
10 Mar 22
CDXC
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.77 mm | 26.77 mm | 26.77 mm | 26.77 mm | 26.77 mm | 26.77 mm |
Cash burn (monthly) | (no burn) | (no burn) | 382.33 k | 572.92 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 2.55 mm | 3.82 mm | n/a | n/a |
Cash remaining | n/a | n/a | 24.23 mm | 22.96 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 63.4 | 40.1 | n/a | n/a |
Institutional ownership, Q2 2023
62.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 61 |
Opened positions | 8 |
Closed positions | 10 |
Increased positions | 11 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 12.59 bn |
Total shares | 47.08 mm |
Total puts | 2.10 k |
Total calls | 7.00 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Champion River Ventures | 7.94 mm | $9.77 mm |
Pioneer Step | 6.92 mm | $8.51 mm |
Shing Li Ka | 6.50 mm | $11.44 mm |
Hoi Shuen Solina Holly Chau | 5.96 mm | $38.73 mm |
Societe des Produits Nestle | 3.82 mm | $5.53 mm |
Li Ka Shing | 3.47 mm | $12.97 mm |
Vanguard | 3.04 mm | $4.78 bn |
Tieton Capital Management | 2.57 mm | $4.04 mm |
ICONIQ Capital | 1.30 mm | $2.04 bn |
Phillip MD Frost Et Al | 1.23 mm | $11.82 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 24 | Brianna Gerber | Employee Stock Options Common Stock | Grant | Acquire A | No | No | 1.52 | 213,886 | 325.11 k | 213,886 |
22 Feb 24 | Fried Robert N | Employee Stock Options Common Stock | Grant | Acquire A | No | No | 1.52 | 399,568 | 607.34 k | 399,568 |
1 Dec 23 | Brianna Gerber | Common Stock | Buy | Acquire P | No | No | 1.41 | 5,000 | 7.05 k | 27,436 |
6 Sep 23 | Champion River Ventures | Common Stock | Buy | Acquire P | Yes | No | 0 | 3,467,778 | 0.00 | 11,408,715 |
12 Aug 23 | Brianna Gerber | Common Stock | Option exercise | Acquire M | No | No | 0 | 22,436 | 0.00 | 22,436 |
12 Aug 23 | Brianna Gerber | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 22,436 | 0.00 | 44,872 |
News
Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $6
9 Apr 24
12 Health Care Stocks Moving In Monday's Intraday Session
18 Mar 24
HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $6
11 Mar 24
Earnings Scheduled For March 6, 2024
6 Mar 24
Earnings Preview For ChromaDex
5 Mar 24
Press releases
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
26 Mar 24
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
6 Mar 24
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
21 Feb 24
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024
5 Feb 24
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
26 Jan 24